Lisata Therapeutics (NASDAQ:LSTA) Trading Down 3.5% – Here’s What Happened

Posted by Stanley Muller on Aug 15th, 2026

Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report) traded down 3.5% on Friday . The company traded as low as $1.05 and last traded at $1.09. Approximately 24,983 shares changed hands during trading, a decline of 81% from the average daily volume of 128,470 shares. The stock had previously closed at $1.13.

Analyst Upgrades and Downgrades

A number of research firms have commented on LSTA. Weiss Ratings lowered Lisata Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research report on Monday, May 18th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lisata Therapeutics presently has a consensus rating of “Reduce” and a consensus target price of $15.00.

Check Out Our Latest Stock Analysis on Lisata Therapeutics

Lisata Therapeutics Stock Down 3.5%

The firm has a fifty day moving average of $2.64 and a 200-day moving average of $3.63. The firm has a market cap of $9.82 million, a P/E ratio of -0.59 and a beta of 0.88.

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter. Sell-side analysts anticipate that Lisata Therapeutics, Inc. will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in Lisata Therapeutics in the second quarter valued at approximately $157,000. BlackRock Inc. bought a new stake in shares of Lisata Therapeutics during the 2nd quarter valued at $187,000. GSA Capital Partners LLP acquired a new position in shares of Lisata Therapeutics in the 2nd quarter valued at $321,000. Rangeley Capital LLC acquired a new position in shares of Lisata Therapeutics in the 1st quarter valued at $376,000. Finally, Renaissance Technologies LLC boosted its position in shares of Lisata Therapeutics by 6.5% in the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock worth $660,000 after purchasing an additional 8,000 shares during the last quarter. 8.94% of the stock is owned by institutional investors.

Lisata Therapeutics Company Profile

(Get Free Report)

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.